MTOR and hepatocellular carcinoma: Another novel agent, MK-2206, an AKT inhibitor, was given in combination with the mTOR kinase inhibitor AZD8055 and MEK inhibitor AZD6244, and preclinical models showed that these agents work synergistically to inhibit cell proliferation in HCC [63].